UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer

SAN DIEGO–(BUSINESS WIRE)–UroGen Announces New Data from the OLYMPUS Trial at SUO 2022
Click here to view original post